Recombinant nucleocapsid-like particles from dengue-2 induce functional serotype-specific cell-mediated immunity in mice

Journal of General Virology

Volumn 93, Issue 6, 2012, Pages 1204-1214

  Gil, Lázaro ^a   Bernardo, Lídice ^b   Pavón, Alequis ^b   Izquierdo, Alienys ^b   Valdés, Iris ^a   Lazo, Laura ^a   Marcos, Ernesto ^a   Romero, Yaremis ^a   Guzmán, María G ^b   Guillén, Gerardo ^a   Hermida, Lisset ^a  

^a CENTER FOR GENETIC ENGINEERING AND BIOTECHNOLOGY   (Cuba)

^b INSTITUTO DE MEDICINA TROPICAL PEDRO KOURÍ   (Cuba)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; NUCLEOCAPSID PROTEIN; PROTEIN C; RECOMBINANT PROTEIN; TUMOR NECROSIS FACTOR ALPHA; VIRUS ANTIBODY;

ANTIBODY RESPONSE; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DENGUE VIRUS 2; HUMORAL IMMUNITY; IMMUNIZATION; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SPLEEN CELL; VIRUS LIKE AGENT; VIRUS NUCLEOCAPSID;

ANIMALS; ANTIBODIES, VIRAL; CAPSID PROTEINS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENGUE; DENGUE VIRUS; FEMALE; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; NUCLEOCAPSID; SPECIES SPECIFICITY; VIRAL VACCINES;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS TYPE 2; MIRIDAE; MUS; PRIMATES;

EID: 84862061796     PISSN: 00221317     EISSN: 14652099     Source Type: Journal    
DOI: 10.1099/vir.0.037721-0     Document Type: Article

References (51)

1. Balsitis, S. J., Williams, K. L., Lachica, R., Flores, D., Kyle, J. L., Mehlhop, E., Johnson, S., Diamond, M. S., Beatty, P. R. & Harris, E. (2010). Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6, e1000790.
2. ++ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes. J Immunol 176, 2817-2824.
3. ++ T cells alter the immune response to heterologous secondary dengue virus infections in mice in a sequence-specific manner. J Infect Dis 197, 608-617.
4. Clements, D. E., Coller, B. A., Lieberman, M. M., Ogata, S., Wang, G., Harada, K. E., Putnak, J. R., Ivy, J. M., McDonell, M. & other authors (2010). Development of a recombinant tetravalent dengue virus vaccine: immunogenicity and efficacy studies in mice and monkeys. Vaccine 28, 2705-2715.
5. Dejnirattisai, W., Duangchinda, T., Lin, C. L., Vasanawathana, S., Jones, M., Jacobs, M., Malasit, P., Xu, X. N., Screaton, G. & Mongkolsapaya, J. (2008). A complex interplay among virus, dendritic cells, T cells, and cytokines in dengue virus infections. J Immunol 181, 5865-5874.
6. Dejnirattisai, W., Jumnainsong, A., Onsirisakul, N., Fitton, P., Vasanawathana, S., Limpitikul, W., Puttikhunt, C., Edwards, C., Duangchinda, T. & other authors (2010). Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745-748.
7. Dong, T., Moran, E., Vinh Chau, N., Simmons, C., Luhn, K., Peng, Y., Wills, B., Phuong Dung, N., Thi Thu Thao, L. & other authors (2007). High pro-inflammatory cytokine secretion and loss of high avidity cross-reactive cytotoxic T-cells during the course of secondary dengue virus infection. PLoS One 2, e1192.
8. ++ T cells from naturally acquired primary dengue virus infection are highly cross-reactive. Immunol Cell Biol 89, 122-129.
9. ++ cytotoxic T-lymphocyte clones. J Virol 70, 141-147.
10. ++ cytotoxic T-lymphocyte clones. J Virol 73, 3623-3629.
11. ++ cells against viral encephalitis in mice. Int Immunol 21, 1175-1183.
12. ++ T-lymphocyte responses in a recipient of an experimental live-attenuated dengue virus type 1 vaccine: bulk culture proliferation, clonal analysis, and precursor frequency determination. J Virol 67, 5962-5967.
13. Gunther, V. J., Putnak, R., Eckels, K. H., Mammen, M. P., Scherer, J. M., Lyons, A., Sztein, M. B. & Sun, W. (2011). A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29, 3895-3904.
14. Guzmán, M. G., Alvarez, M., Rodríguez, R., Rosario, D., Vázquez, S., Valdés, L., Cabrera, M. V. & Kourí, G. (1999). Fatal dengue hemorrhagic fever in Cuba, 1997. Int J Infect Dis 3, 130-135.
15. Halstead, S. B. (1988). Pathogenesis of dengue: challenges to molecular biology. Science 239, 476-481.
16. Halstead, S. B. (1989). Antibody, macrophages, dengue virus infection, shock, and hemorrhage: a pathogenetic cascade. Rev Infect Dis 11 (Suppl. 4), S830-S839.
17. Hatch, S., Endy, T. P., Thomas, S., Mathew, A., Potts, J., Pazoles, P., Libraty, D. H., Gibbons, R. & Rothman, A. L. (2011). Intracellular cytokine production by dengue virus-specific T cells correlates with subclinical secondary infection. J Infect Dis 203, 1282-1291.
18. Imrie, A., Meeks, J., Gurary, A., Sukhbataar, M., Kitsutani, P., Effler, P. & Zhao, Z. (2007). Differential functional avidity of dengue virusspecific T-cell clones for variant peptides representing heterologous and previously encountered serotypes. J Virol 81, 10081-10091.
19. Irie, K., Mohan, P. M., Sasaguri, Y., Putnak, R. & Padmanabhan, R. (1989). Sequence analysis of cloned dengue virus type 2 genome (New Guinea-C strain). Gene 75, 197-211.
20. Kaufman, B. M., Summers, P. L., Dubois, D. R. & Eckels, K. H. (1987). Monoclonal antibodies against dengue 2 virus E-glycoprotein protect mice against lethal dengue infection. Am J Trop Med Hyg 36, 427-434.
21. Khan, A. M., Heiny, A. T., Lee, K. X., Srinivasan, K. N., Tan, T. W., August, J. T. & Brusic, V. (2006). Large-scale analysis of antigenic diversity of T-cell epitopes in dengue virus. BMC Bioinformatics 7 (Suppl. 5), S4.
22. Khan, A. M., Miotto, O., Nascimento, E. J., Srinivasan, K. N., Heiny, A. T., Zhang, G. L., Marques, E. T., Tan, T. W., Brusic, V. & other authors (2008). Conservation and variability of dengue virus proteins: implications for vaccine design. PLoS Negl Trop Dis 2, e272.
23. Khromykh, A. A. & Westaway, E. G. (1996). RNA binding properties of core protein of the flavivirus Kunjin. Arch Virol 141, 685-699.
24. Kuhn, R. J., Zhang, W., Rossmann, M. G., Pletnev, S. V., Corver, J., Lenches, E., Jones, C. T., Mukhopadhyay, S., Chipman, P. R. & Strauss, E. G. (2002). Structure of dengue virus: implications for flavivirus organization, maturation, and fusion. Cell 108, 717-725.
25. Lazo, L., Hermida, L., Zulueta, A., Sánchez, J., López, C., Silva, R., Guillén, G. & Guzmán, M. G. (2007). A recombinant capsid protein from dengue-2 induces protection in mice against homologous virus. Vaccine 25, 1064-1070.
26. Libraty, D. H., Endy, T. P., Houng, H. S., Green, S., Kalayanarooj, S., Suntayakorn, S., Chansiriwongs, W., Vaughn, D. W., Nisalak, A. & other authors (2002). Differing influences of virus burden and immune activation on disease severity in secondary dengue-3 virus infections. J Infect Dis 185, 1213-1221.
27. ++ cytotoxic T lymphocyte (CTL) clones. Recognition of NS3 amino acids 500 to 508 by CTL clones of two different serotype specificities. J Immunol 154, 1287-1295.
28. López, C., Gil, L., Lazo, L., Menéndez, I., Marcos, E., Sánchez, J., Valdés, I., Falcón, V., de la Rosa, M. C. & other authors (2009). In vitro assembly of nucleocapsid-like particles from purified recombinant capsid protein of dengue-2 virus. Arch Virol 154, 695-698.
29. ++ T cells to heterologous serotypes. J Immunol 175, 2676-2683.
30. ++ cytotoxic T lymphocytes of dengue virus nonstructural proteins NS3 and NS1.2a. J Clin Invest 98, 1684-1691.
31. Mongkolsapaya, J., Dejnirattisai, W., Xu, X. N., Vasanawathana, S., Tangthawornchaikul, N., Chairunsri, A., Sawasdivorn, S., Duangchinda, T., Dong, T. & other authors (2003). Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med 9, 921-927.
32. Mongkolsapaya, J., Duangchinda, T., Dejnirattisai, W., Vasanawathana, S., Avirutnan, P., Jairungsri, A., Khemnu, N., Tangthawornchaikul, N., Chotiyarnwong, P. & other authors (2006). T cell responses in dengue hemorrhagic fever: are crossreactive T cells suboptimal? J Immunol 176, 3821-3829.
33. Morens, D. M. (1994). Antibody-dependent enhancement of infection and the pathogenesis of viral disease. Clin Infect Dis 19, 500-512.
34. Morens, D. M., Halstead, S. B., Repik, P. M., Putvatana, R. & Raybourne, N. (1985). Simplified plaque reduction neutralization assay for dengue viruses by semimicro methods in BHK-21 cells: comparison of the BHK suspension test with standard plaque reduction neutralization. J Clin Microbiol 22, 250-254.
35. Mukhopadhyay, S., Kuhn, R. J. & Rossmann, M. G. (2005). A structural perspective of the flavivirus life cycle. Nat Rev Microbiol 3, 13-22.
36. Riedl, P., Stober, D., Oehninger, C., Melber, K., Reimann, J. & Schirmbeck, R. (2002). Priming Th1 immunity to viral core particles is facilitated by trace amounts of RNA bound to its arginine-rich domain. J Immunol 168, 4951-4959.
37. Rothman, A. L. (2003). Immunology and immunopathogenesis of dengue disease. Adv Virus Res 60, 397-419.
38. Rothman, A. L. (2004). Dengue: defining protective versus pathologic immunity. J Clin Invest 113, 946-951.
39. Sabin, A. B. (1952). Research on dengue during World War II. Am J Trop Med Hyg 1, 30-50.
40. Sangkawibha, N., Rojanasuphot, S., Ahandrik, S., Viriyapongse, S., Jatanasen, S., Salitul, V., Phanthumachinda, B. & Halstead, S. B. (1984). Risk factors in dengue shock syndrome: a prospective epidemiologic study in Rayong, Thailand. I. The 1980 outbreak. Am J Epidemiol 120, 653-669.
41. Shresta, S., Kyle, J. L., Snider, H. M., Basavapatna, M., Beatty, P. R. & Harris, E. (2004). Interferon-dependent immunity is essential for resistance to primary dengue virus infection in mice, whereas T- and B-cell-dependent immunity are less critical. J Virol 78, 2701-2710.
42. Simmons, M., Nelson, W. M., Wu, S. J. & Hayes, C. G. (1998). Evaluation of the protective efficacy of a recombinant dengue envelope B domain fusion protein against dengue 2 virus infection in mice. Am J Trop Med Hyg 58, 655-662.
43. Takeshita, F., Leifer, C. A., Gursel, I., Ishii, K. J., Takeshita, S., Gursel, M. & Klinman, D. M. (2001). Cutting edge: role of Toll-like receptor 9 in CpG DNA-induced activation of human cells. J Immunol 167, 3555-3558.
44. + T-cell response. J Virol 74, 8094-8101.
45. + T cells in the central nervous system after dengue virus encephalitis. Int Immunol 15, 119-125.
46. Vollmer, J. (2006). CpG motifs to modulate innate and adaptive immune responses. Int Rev Immunol 25, 125-134.
47. Yauch, L. E. & Shresta, S. (2008). Mouse models of dengue virus infection and disease. Antiviral Res 80, 87-93.
48. ++ T cells. J Immunol 182, 4865-4873.
49. ++ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185, 5405-5416.
50. Zellweger, R. M., Prestwood, T. R. & Shresta, S. (2010). Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease. Cell Host Microbe 7, 128-139.
51. Zivny, J., DeFronzo, M., Jarry, W., Jameson, J., Cruz, J., Ennis, F. A. & Rothman, A. L. (1999). Partial agonist effect influences the CTL response to a heterologous dengue virus serotype. J Immunol 163, 2754-2760.